» Articles » PMID: 18484635

Screening for Copy-number Alterations and Loss of Heterozygosity in Chronic Lymphocytic Leukemia--a Comparative Study of Four Differently Designed, High Resolution Microarray Platforms

Abstract

Screening for gene copy-number alterations (CNAs) has improved by applying genome-wide microarrays, where SNP arrays also allow analysis of loss of heterozygozity (LOH). We here analyzed 10 chronic lymphocytic leukemia (CLL) samples using four different high-resolution platforms: BAC arrays (32K), oligonucleotide arrays (185K, Agilent), and two SNP arrays (250K, Affymetrix and 317K, Illumina). Cross-platform comparison revealed 29 concordantly detected CNAs, including known recurrent alterations, which confirmed that all platforms are powerful tools when screening for large aberrations. However, detection of 32 additional regions present in 2-3 platforms illustrated a discrepancy in detection of small CNAs, which often involved reported copy-number variations. LOH analysis using dChip revealed concordance of mainly large regions, but showed numerous, small nonoverlapping regions and LOH escaping detection. Evaluation of baseline variation and copy-number ratio response showed the best performance for the Agilent platform and confirmed the robustness of BAC arrays. Accordingly, these platforms demonstrated a higher degree of platform-specific CNAs. The SNP arrays displayed higher technical variation, although this was compensated by high density of elements. Affymetrix detected a higher degree of CNAs compared to Illumina, while the latter showed a lower noise level and higher detection rate in the LOH analysis. Large-scale studies of genomic aberrations are now feasible, but new tools for LOH analysis are requested.

Citing Articles

Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2.

Bhoi S, Ljungstrom V, Baliakas P, Mattsson M, Smedby K, Juliusson G Epigenetics. 2016; 11(6):449-55.

PMID: 27128508 PMC: 4939912. DOI: 10.1080/15592294.2016.1178432.


DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes.

La-Touche S, Lemetre C, Lambros M, Stankiewicz E, Ng C, Weigelt B PLoS One. 2016; 11(2):e0146740.

PMID: 26901676 PMC: 4763861. DOI: 10.1371/journal.pone.0146740.


Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.

Vujkovic M, Attiyeh E, Ries R, Horn M, Goodman E, Ding Y Cancer Genet. 2015; 208(7-8):408-13.

PMID: 26163103 PMC: 4523450. DOI: 10.1016/j.cancergen.2015.04.010.


Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Ng C, Martelotto L, Gauthier A, Wen H, Piscuoglio S, Lim R Genome Biol. 2015; 16:107.

PMID: 25994018 PMC: 4440518. DOI: 10.1186/s13059-015-0657-6.


Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?.

Alsolami R, Knight S, Schuh A Per Med. 2014; 10(4):361-376.

PMID: 24611071 PMC: 3943176. DOI: 10.2217/pme.13.33.